De-novo metastatic castration sensitive prostate cancer (mCSPC)is a subgroup of prostate cancer associated with poor prognosis. Recently, the treatment of mCSPC has been enriched by new life-prolonging options, including the combination of docetaxel or abiraterone acetate with androgen deprivation therapy (ADT). Of note, the advantage of chemohormonal therapy was more relevant in the subgroup of high-volume disease compared to low-volume, while the survival prolongation of abiraterone was observed only in high-risk patients. Choosing the most appropriate therapy is one of the most debated issues. This review describes the latest news on de-novo mCSPC to better outline patients' management. At the ESMO 2018 Congress two novel studies focused on this setting have been presented, trying to define the role of radiotherapy to the primary tumour and the efficacy of abiraterone acetate in the subset of low-risk patients. We have analysed these results in light of the evidence already available.

Iacovelli, R., Ciccarese, C., Schinzari, G., Maiorano, B. A., Rossi, E., Pierconti, F., Bassi, P. F., Bria, E., Tortora, G., Going towards a precise definition of the therapeutic management of de-novo metastatic castration sensitive prostate cancer patients: How prognostic classification impact treatment decisions, <<CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY>>, 2019; 139 (Luglio): 83-86. [doi:10.1016/j.critrevonc.2019.05.005] [http://hdl.handle.net/10807/139993]

Going towards a precise definition of the therapeutic management of de-novo metastatic castration sensitive prostate cancer patients: How prognostic classification impact treatment decisions

Iacovelli R.;Ciccarese C.;Schinzari G.;Maiorano B. A.;Rossi E.;Pierconti F.;Bria E.;Tortora G.
2019

Abstract

De-novo metastatic castration sensitive prostate cancer (mCSPC)is a subgroup of prostate cancer associated with poor prognosis. Recently, the treatment of mCSPC has been enriched by new life-prolonging options, including the combination of docetaxel or abiraterone acetate with androgen deprivation therapy (ADT). Of note, the advantage of chemohormonal therapy was more relevant in the subgroup of high-volume disease compared to low-volume, while the survival prolongation of abiraterone was observed only in high-risk patients. Choosing the most appropriate therapy is one of the most debated issues. This review describes the latest news on de-novo mCSPC to better outline patients' management. At the ESMO 2018 Congress two novel studies focused on this setting have been presented, trying to define the role of radiotherapy to the primary tumour and the efficacy of abiraterone acetate in the subset of low-risk patients. We have analysed these results in light of the evidence already available.
eng
www.elsevier.com/locate/critrevonc
Iacovelli, R., Ciccarese, C., Schinzari, G., Maiorano, B. A., Rossi, E., Pierconti, F., Bassi, P. F., Bria, E., Tortora, G., Going towards a precise definition of the therapeutic management of de-novo metastatic castration sensitive prostate cancer patients: How prognostic classification impact treatment decisions, <>, 2019; 139 (Luglio): 83-86. [doi:10.1016/j.critrevonc.2019.05.005] [http://hdl.handle.net/10807/139993]
File in questo prodotto:
File Dimensione Formato  
139993.pdf

non disponibili

Tipologia file ?: Versione Editoriale (PDF)
Licenza: Non specificato
Dimensione 512.53 kB
Formato Unknown
512.53 kB Unknown   Visualizza/Apri   Contatta l'autore

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/139993
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 6
  • ???jsp.display-item.citation.isi??? 6
social impact